Vanda Pharmaceuticals Inc [VNDA] stock prices are up 3.49% to $6.23 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The VNDA shares have gain 17.11% over the last week, with a monthly amount drifted -4.15%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Vanda Pharmaceuticals Inc [NASDAQ: VNDA] stock has seen the most recent analyst activity on July 11, 2024, when Cantor Fitzgerald initiated its Overweight rating and assigned the stock a price target of $11. Previously, Jefferies downgraded its rating to Hold on February 25, 2022, and dropped its price target to $12. On May 12, 2021, BofA Securities initiated with a Buy rating and assigned a price target of $22 on the stock. Citigroup downgraded its rating to a Neutral but stick to its price target of $14 on January 14, 2021. Citigroup upgraded its rating to a Buy but $14 remained the price target by the analyst firm on October 29, 2020. Citigroup downgraded its rating to Neutral for this stock on June 09, 2020, but kept the price target unchanged to $14. In a note dated March 16, 2020, Oppenheimer downgraded an Underperform rating on this stock.
The stock price of Vanda Pharmaceuticals Inc [VNDA] has been fluctuating between $3.30 and $6.75 over the past year. Currently, Wall Street analysts expect the stock to reach $11 within the next 12 months. Vanda Pharmaceuticals Inc [NASDAQ: VNDA] shares were valued at $6.23 at the most recent close of the market. An investor can expect a potential return of 76.57% based on the average VNDA price forecast.
Analyzing the VNDA fundamentals
The Vanda Pharmaceuticals Inc [NASDAQ:VNDA] reported sales of 177.60M for trailing twelve months, representing a drop of -24.06%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.02%, and Net Profit Margin reading is -0.03%. To continue investigating profitability, this company’s Return on Assets is posted at -0.01, Equity is -0.01 and Total Capital is -0.05. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.10 points at the first support level, and at 5.97 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.31, and for the 2nd resistance point, it is at 6.39.
Ratios To Look Out For
It’s worth pointing out that Vanda Pharmaceuticals Inc [NASDAQ:VNDA]’s Current Ratio is 4.71. On the other hand, the Quick Ratio is 4.69, and the Cash Ratio is 1.34. Considering the valuation of this stock, the price to sales ratio is 2.04, the price to book ratio is 0.67.
Transactions by insiders
Recent insider trading involved Polymeropoulos Mihael Hristos, President and CEO, that happened on Mar 05 ’24 when 24288.0 shares were sold. SVP, Chief Marketing Officer, Wijkstrom Joakim completed a deal on Mar 05 ’24 to sell 9229.0 shares. Meanwhile, SVP, CFO & Treasurer Moran Kevin Patrick sold 8902.0 shares on Mar 05 ’24.
